Ungogo Marzuq A, Mohammed Mustapha, Umar Bala N, Bala Auwal A, Khalid Garba M
Department of Veterinary Pharmacology and Toxicology, Ahmadu Bello University, Zaria 810107, Kaduna State, Nigeria.
Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, United Kingdom.
Biosaf Health. 2021 Jun;3(3):148-155. doi: 10.1016/j.bsheal.2021.01.001. Epub 2021 Jan 9.
The novel coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak in the last two decades. Emerging and re-emerging infections like COVID-19 pose serious challenges of the paucity of information and lack of specific cure or vaccines. This leaves utilisation of existing scientific data on related viral infections and repurposing relevant aetiologic and supportive therapies as the best control approach while novel strategies are developed and trialled. Many promising antiviral agents including lopinavir, ritonavir, remdesivir, umifenovir, darunavir, and oseltamivir have been repurposed and are currently trialled for the care for COVID-19 patients. Adjunct therapies for the management of symptoms and to provide support especially in severe and critically ill patients have also been identified. This review provides an appraisal of the current evidence for the rational use of frontline therapeutics in the management of COVID-19. It also includes updates regarding COVID-19 immunotherapy and vaccine development.
2019年新型冠状病毒病（COVID-19）是过去二十年来第三次冠状病毒爆发。像COVID-19这样的新出现和再次出现的感染对信息匮乏以及缺乏特效治疗方法或疫苗构成了严峻挑战。在开发和试验新策略的同时，利用现有关于相关病毒感染的科学数据以及重新利用相关病因和支持性疗法是最佳的控制方法。许多有前景的抗病毒药物，包括洛匹那韦、利托那韦、瑞德西韦、乌米芬诺韦、达芦那韦和奥司他韦，已经被重新利用，目前正在对COVID-19患者的治疗进行试验。还确定了用于管理症状以及特别是为重症和危重症患者提供支持的辅助治疗方法。本综述对目前合理使用一线治疗方法来管理COVID-19的证据进行了评估。它还包括关于COVID-19免疫治疗和疫苗开发的最新情况。
